clinical trial · NCT06914869
Drug-Drug Interaction Potential of Mavorixafor
X4 Pharmaceuticals·phase1·completed·n = 38
Healthy ParticipantsMavorixaforCarbamazepineEfavirenz
brief summary
The main purpose of this study is to evaluate drug-drug interaction (DDI) of orally administered mavorixafor with cytochrome P3A (CYP3A) inducers carbamazepine (a strong CYP3A inducer) or efavirenz (a moderate CYP3A inducer) in healthy male and female participants.
started
Feb 18, 2025
primary completion
May 19, 2025
completion
May 19, 2025
last updated
Jul 1, 2025
official title
A Phase I, Randomized, Open-label, Drug-drug Interaction Study to Assess the Effect of Multiple Doses of a Moderate and a Strong CYP3A Inducer on the Pharmacokinetics and Safety of Mavorixafor in Healthy Male and Female Participants
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol